Patients received either bevacizumab ( @ mg/kg ) + XELOX ( capecitabine @,@ mg/m ( @ ) twice daily on days @-@ + oxaliplatin @ mg/m ( @ ) on day @ every @ weeks ) until disease progression ( arm A ) or the same doses of bevacizumab + XELOX for @ cycles followed by bevacizumab + capecitabine until disease progression ( arm B ) .